Patents by Inventor Michael G. Palfreyman

Michael G. Palfreyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NMDA antagonism method
    Patent number: 5547991
    Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: July 17, 1995
    Date of Patent: August 20, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Ian A. McDonald, Francesco G. Salituro, Robert Schwarcz
  • NMDA antagonists
    Patent number: 5484814
    Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: December 10, 1993
    Date of Patent: January 16, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Ian Alexander McDonald, Francesco G. Salituro, Robert Schwarcz
  • NMDA antagonists
    Patent number: 5470870
    Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: November 28, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Ian A. McDonald, Francesco G. Salituro, Robert Schwarcz, Bruce M. Baron
  • NMDA antagonists
    Patent number: 5360814
    Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: January 25, 1994
    Date of Patent: November 1, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Ian A. McDonald, Francesco G. Salituro, Robert Schwarcz, Bruce M. Baron
  • Inhibitors of lysyl oxidase
    Patent number: 5252608
    Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.
    Type: Grant
    Filed: June 10, 1992
    Date of Patent: October 12, 1993
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Philippe Bey, Ian A. McDonald
  • Lactamimides as calcium antagonists
    Patent number: 5198433
    Abstract: Applicants have discovered that certain previously known lactamimide derivatives possess, as a class, valuable calcium channel blocking activity. By virtue of this calcium antagonism activity the compounds are antihypertensives and will have other activities associated with calcium antagonists.
    Type: Grant
    Filed: July 21, 1992
    Date of Patent: March 30, 1993
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Norbert L. Wiech, Hsien C. Cheng, John M. Kane
  • Inhibitors of lysyl oxidase
    Patent number: 5182297
    Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.
    Type: Grant
    Filed: March 6, 1991
    Date of Patent: January 26, 1993
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Philippe Bey, Ian A. McDonald
  • Lactamimides as calcium antagonists
    Patent number: 5158945
    Abstract: Applicants have discovered that certain previously known lactamimide derivatives possess, as a class, valuable calcium channel blocking activity. By virtue of this calcium antagonism activity the compounds are antihypertensives and will have other activities associated with calcium antagonists.
    Type: Grant
    Filed: March 11, 1992
    Date of Patent: October 27, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Hsien C. Cheng, Norbert L. Wiech, John M. Kane
  • Lactamimides as calcium antagonists
    Patent number: 5128337
    Abstract: Applicants have discovered that certain previously known lactamimide derivatives possess, as a class, valuable calcium channel blocking activity. By virtue of this calcium antagonism activity the compounds are antihypertensives and will have other activities associated with calcium antagonists.
    Type: Grant
    Filed: September 23, 1991
    Date of Patent: July 7, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Norbert L. Wiech, Hsien C. Cheng, John M. Kane
  • Lactamimides as calcium antagonists
    Patent number: 5082837
    Abstract: Applicants have discovered that certain previously known lactamimide derivatives possess, as a class, valuable calcium channel blocking activity. By virtue of this calcium antagonism activity the compounds are antihypertensives and will have other activites associated with calcium antagonists.
    Type: Grant
    Filed: November 29, 1990
    Date of Patent: January 21, 1992
    Assignee: Merrell Dow Pharmaceuticals
    Inventors: Michael G. Palfreyman, Norbert L. Wiech, Hsien C. Cheng, John M. Kane
  • Inhibitors of lysyl oxidase
    Patent number: 5059714
    Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.
    Type: Grant
    Filed: January 9, 1991
    Date of Patent: October 22, 1991
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Philippe Bey, Ian A. McDonald
  • Inhibitors of lysyl oxidase
    Patent number: 5021456
    Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.
    Type: Grant
    Filed: May 4, 1990
    Date of Patent: June 4, 1991
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Philippe Bey, Ian A. McDonald
  • Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
    Patent number: 5011846
    Abstract: The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of a medicament for the treatment of anxiety, psychosis, glaucoma and for the stimulation of gastric motility.
    Type: Grant
    Filed: May 16, 1990
    Date of Patent: April 30, 1991
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Maurice W. Gittos, Francis P. Miller, Stephen M. Sorensen, John R. Fozard, Paul Moser, Michael G. Palfreyman, Hsien Cheng
  • Lactamimides as calcium antagonists
    Patent number: 5010072
    Abstract: Applicants have discovered that certain previously known lactamimide derivatives possess, as a class, valuable calcium channel blocking activity. By virtue of this calcium antagonism activity the compounds are antihypertensives and will have other activities associated with calcium antagonists.
    Type: Grant
    Filed: June 28, 1988
    Date of Patent: April 23, 1991
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Norbert L. Wiech, Hsien C. Cheng, John M. Kane
  • Inhibitors of lysyl oxidase
    Patent number: 4965288
    Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.
    Type: Grant
    Filed: September 19, 1989
    Date of Patent: October 23, 1990
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Philippe Bey, Ian A. McDonald
  • Inhibitors of lysyl oxidase
    Patent number: 4943593
    Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.
    Type: Grant
    Filed: September 19, 1989
    Date of Patent: July 24, 1990
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Ian A. McDonald, Philippe Bey
  • Method of treating parkinson's syndrome
    Patent number: 4916151
    Abstract: Novel nonaromatic fluoroallylamines are potent MAO inhibitors and at low dose selectively inhibit MAO-B. They are useful in the treatment of depression and co-administration with L-dopa and decarboxylase inhibitors, in the treatment of Parkinsonism.
    Type: Grant
    Filed: March 10, 1989
    Date of Patent: April 10, 1990
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Philippe Bey, Michael G. Palfreyman, Ian A. McDonald
  • Antiepileptic pyrazolopyridines
    Patent number: 4916140
    Abstract: The disclosure pertains to certain pyrazolopyridincarboxylates which are calcium channel blockers and possess anticonvulsant properties. By virtue of this activity, the compounds are useful in the treatment of epilepsy.
    Type: Grant
    Filed: September 28, 1988
    Date of Patent: April 10, 1990
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Francis P. Miller, Anis Mir
  • Use of .beta.-(fluoromethylene)-5-hydroxytryptophan and derivatives as prodrugs and mao inhibition
    Patent number: 4879305
    Abstract: This invention relates to pharmacologically-active novel compounds comprising .beta.-fluoromethylene-5-hydroxytryptophan and derivatives, to methods of inhibiting monoamine oxidase and to treating depression, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: December 2, 1988
    Date of Patent: November 7, 1989
    Assignee: Merrell Dow Pharmaceuticals
    Inventors: Ian A. McDonald, Michael G. Palfreyman, Jean-Noel Collard
  • .beta.-(Fluoromethylene)-5-hydroxytryptophan and derivatives and their use as prodrugs for MAO inhibition
    Patent number: 4822812
    Abstract: This invention relates to pharmacologically-active novel compounds comprising .beta.-fluoromethylene-5-hydroxytryptophan and derivatives, to methods of inhibiting monoamine oxidase and to treating depression, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: May 21, 1987
    Date of Patent: April 18, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Ian A. McDonald, Michael G. Palfreyman, Jean-Noel Collard